SCHEMBL10044874

SCHEMBL10044874

CC(=O)/C=C/CC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11918301 0.80
SCHEMBL2569752 0.79
SCHEMBL8150538 0.79
SCHEMBL11025123 0.77 ALDH1A1 (0.50)
Glutaconate SCHEMBL21841 0.77
Glutaconate SCHEMBL12230 0.77
Glutaconate SCHEMBL688877 0.77
Glutaconate SCHEMBL2514167 0.77 ALDH1A1 (0.65)
SCHEMBL16964957 0.76
SCHEMBL4078133 0.76 CYP2D6 (0.73)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240071588-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC (US) 2024-02-29 US disclosed
US-20230398226-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-11833213-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
US-11833154-B2 Methods of treatment of myeloproliferative neoplasm MEMORIAL SLOAN KETTERING CANCER CENTER (US) 2023-12-05 US disclosed
US-20230346789-A1 METHODS OF TREATING ENHANCING BRAIN TUMORS USING COMBINATION THERAPY MSD INT GMBH (CH) 2023-11-02 US disclosed
US-20230287365-A1 COMPOSITIONS AND METHODS FOR DECREASING INFLAMMATION BETH ISRAEL DEACONESS MEDICAL CENTER, INC. 2023-09-14 US disclosed
US-20230277514-A1 THERAPY FOR TREATING MALIGNANCIES AGIOS PHARMACEUTICALS, INC. 2023-09-07 US disclosed
US-20230250078-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC (US) 2023-08-10 US disclosed
US-20230190950-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS CIDARA THERAPEUTICS, INC. 2023-06-22 US disclosed
US-11667673-B2 Therapeutically active compounds and their methods of use SERVIER PHARMACEUTICALS LLC (US) 2023-06-06 US disclosed
US-20140213580-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2014-07-31 US disclosed
US-20140206673-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2014-07-24 US disclosed
US-8778645-B2 Method for the production of glutaconate BASF SE (DE) 2014-07-15 US disclosed
US-20130288284-A1 METHODS AND COMPOSITIONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-10-31 US disclosed
US-20130197106-A1 METHODS OF IDENTIFYING A CANDIDATE COMPOUND AGIOS PHARMACEUTICALS, INC (US) 2013-08-01 US disclosed
US-20130190249-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2013-07-25 US disclosed
US-20130190287-A1 THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC. (US) 2013-07-25 US disclosed
US-20130183281-A1 METHODS AND COMPOSITONS FOR CELL-PROLIFERATION-RELATED DISORDERS SERVIER PHARMACEUTICALS LLC 2013-07-18 US disclosed
US-20130184222-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2013-07-18 US disclosed
US-20120021472-A1 Method for the Production of Glutaconate BASF SE (DE) 2012-01-26 US disclosed